RxDoctor Payments Data

Nilda Olmeda

Family · Edinburg, TXNPI 1548513229

Payments from drug & device makers

$1,222in general payments, 2019–2025

Across 81 payments — averaging $15.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$512
  • Lilly USA, LLC$314
  • AstraZeneca$105
  • GSK$64
  • Sanofi-aventis U.S. LLC$59
  • Kowa Pharmaceuticals America, Inc.$54
  • plus $114 from 4 others

What the payments were for

  • Food & beverage$1,21199%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,222 in reported general payments places this provider in the 70th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$17,020
Medicare patients
29
Services billed
265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$53,649
JardianceEmpagliflozin17$22,957
MounjaroTirzepatide22$22,633
LinzessLinaclotide31$21,943
FarxigaDapagliflozin Propanediol18$17,935
JanuviaSitagliptin Phosphate15$14,926
EntrestoSacubitril/Valsartan12$10,292
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$4,365
Atorvastatin Calcium136$2,037
Metoprolol Succinate73$1,570
Gabapentin53$1,187
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip42$977
Tamsulosin Hcl41$785
Rosuvastatin Calcium43$621
Levothyroxine Sodium56$521

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$512$53,64942 claims
Lilly USA, LLCMounjaro$314$22,63322 claims
AstraZenecaFarxiga$105$17,93518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 15,456 family providers in Texas.

Other family in Edinburg

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →